These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 9715503)

  • 1. [Influence of pharmacologic cholesterol-lowering on the utilization of resources in health care--Significance of the Scandinavian Simvastatin Survival Study for cost reduction under Swiss conditions].
    Steurer J
    Schweiz Med Wochenschr; 1998 Jul; 128(29-30):1150-1. PubMed ID: 9715503
    [No Abstract]   [Full Text] [Related]  

  • 2. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
    Szucs TD; Lüscher TF; Gutzwiller F
    Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SBU should investigate what is an evidence-based and cost-effective use of statins].
    Hjemdahl P; Allhammar A; Heaton C; Hulting J; Kahan T; Malmström R; Martinsson A; Rücker F; Schenck-Gustafsson K; Schwieler J; Törnerud M; Wettermark B
    Lakartidningen; 2009 Aug 5-18; 106(32-33):1992-4. PubMed ID: 19764381
    [No Abstract]   [Full Text] [Related]  

  • 4. [Coronary heart disease patient reaches LDL level of 100 mg/dl with atorvastatin: how do you continue treatment next year?].
    Weizel A; Sawicki PT
    MMW Fortschr Med; 2004 Dec; 146(51-52):14, 16. PubMed ID: 15675236
    [No Abstract]   [Full Text] [Related]  

  • 5. [Simvastatin 40 mg as secondary prophylaxis: Effective, tolerable and cost-efficient!].
    Hernborg A; Hjemdahl P; Håkansson J
    Lakartidningen; 2006 Mar 15-21; 103(11):858, 861; discussion 861-2. PubMed ID: 16613120
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of statin medications.
    Kaplan RM; Golomb BA
    Am Psychol; 2001 Apr; 56(4):366-7. PubMed ID: 11330239
    [No Abstract]   [Full Text] [Related]  

  • 7. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL; Cox ER
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative economic analysis of simvastatin versus atorvastatin: results of the Surrogate Marker Cost-Efficacy (SMaC) study.
    Badia X; Russo P; Attanasio E
    Clin Ther; 1999 Oct; 21(10):1788-96. PubMed ID: 10566573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe--an update.
    Drug Ther Bull; 2009 Aug; 47(8):91-5. PubMed ID: 19654419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial.
    Jönsson B; Cook JR; Pedersen TR
    Diabetologia; 1999 Nov; 42(11):1293-301. PubMed ID: 10550412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating economic analysis into clinical trials.
    Imai K; Zhang P
    Lancet; 2005 May 21-27; 365(9473):1749-50. PubMed ID: 15910936
    [No Abstract]   [Full Text] [Related]  

  • 12. [The 4S study is analysed. Cholesterol reduction is cost-efficient].
    Jönsson B; Johannesson M; Olsson AG
    Lakartidningen; 1997 Dec; 94(51-52):4931-4. PubMed ID: 9454018
    [No Abstract]   [Full Text] [Related]  

  • 13. Assessing the appropriateness of combining economic data from multinational clinical trials.
    Cook JR; Drummond M; Glick H; Heyse JF
    Stat Med; 2003 Jun; 22(12):1955-76. PubMed ID: 12802815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for a major coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment.
    Wilhelmsen L; Pyörälä K; Wedel H; Cook T; Pedersen T; Kjekshus J
    Eur Heart J; 2001 Jul; 22(13):1119-27. PubMed ID: 11428852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
    Keiding H; Hildebrandt P; Alemao E; Davies GM
    Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RE: M Thomas. The change of cost: reference-based pricing and the statins. 1999;15:535-8.
    McNee W
    Can J Cardiol; 1999 Nov; 15(11):1287. PubMed ID: 10841625
    [No Abstract]   [Full Text] [Related]  

  • 17. Blood glucose and the metabolism of cholesterol in coronary patients with and without simvastatin treatment.
    Miettinen TA; Gylling H;
    Clin Chim Acta; 2007 Apr; 379(1-2):53-8. PubMed ID: 17258182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Be careful about pseudo-information on cost-effectiveness].
    Lindberg M
    Lakartidningen; 1998 Jan; 95(3):144. PubMed ID: 9467283
    [No Abstract]   [Full Text] [Related]  

  • 20. [Contribution to statins?].
    Heebøll-Nielsen NC; Ahnfeldt-Mollerup I
    Ugeskr Laeger; 1998 Sep; 160(37):5376-7. PubMed ID: 9748871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.